首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

2126331

次世代定序市場：策略性洞察與預測（2026-2035 年）

Next-Generation Sequencing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月03日 | 出版商:

Knowledge Sourcing Intelligence | 英文 165 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計次世代定序市場規模將從 2026 年的 249 億美元成長到 2035 年的 842 億美元，複合年成長率為 14.5%。

次世代定序市場正經歷根本性的變革，其驅動力源於精準醫療的模式轉移以及將全面的基因組資訊整合到常規臨床實踐中。這一市場演變的特點是，人們日益認知到次世代定序（NGS）能夠同時分析數百萬個核酸片段，從而提供對個人化醫療至關重要的基因組、轉錄組、表觀基因和元基因組的全面資訊。先進的定序化學、自動化、人工智慧和基於雲端的生物資訊學的融合，使得基因組分析更加快速、準確且日益普及。傳統的診斷方法在生物標記識別方面能力有限，而NGS可以在單一分析流程中識別多個具有臨床意義的變異，從而減少所需的檢測次數並提高診斷可靠性，促使醫療系統將NGS整合到常規診斷流程中。隨著大規模人群定序有助於疾病監測、罕見疾病診斷和醫療保健規劃，政府機構正在支持國家級基因組舉措。製藥公司正在擴大以生物標記主導的臨床試驗，從而持續推動對定序技術的需求，以支持伴隨診斷的開發和轉化研究。透過對整合定序生態系統、人工智慧驅動的分析平台和長讀長技術的大量投資，NGS 正成為支撐全球醫療保健系統精準醫療持續發展的基礎技術。

市場促進因素

精準腫瘤學的擴展是次世代定序市場發展的主要動力。隨著現代癌症治療越來越依賴分析腫瘤的定位以及基因組特徵，精準腫瘤學已成為臨床應用最廣泛的領域。由於腫瘤科醫師需要同時識別影響標靶治療選擇的多種可治療突變，醫院正在擴展全面的基因組分析計畫。傳統的分子檢測方法在生物標記方面的能力有限，當需要進行序貫檢測時，會導致診斷延遲。診斷設備製造商正透過與開發標靶治療的製藥公司合作，擴展其基於NGS（次世代定序）的腫瘤產品組合，從而持續提高定序的使用率。罕見疾病診斷的增加透過基因組檢測的廣泛應用進一步加速了市場成長。由於罕見疾病通常由遺傳性基因異常引起，因此當傳統檢測無法得出結論時，全面的定序是一種有效的診斷工具。醫療機構正擴大將EXOME和基因測序納入其診斷流程，因為早期分子診斷可以縮短冗長的診斷過程，並支持適當的臨床管理。隨著兒童和成人群體對基因疾病檢測的需求不斷成長，診斷檢測實驗室持續投資於高通量定序基礎設施。製藥業的生物標記開發正推動定序的應用，並將其日益融入臨床試驗。標靶治療需要在臨床開發過程中識別具有特定基因特徵的患者群體，這使得藥物研發越來越依賴分子層面的分層。製藥公司正在將定序整合到藥物研發、轉化研究和臨床試驗的各個階段，以改善生物標記的識別和治療反應的評估。這項需求正在加強定序平台提供者與生物製藥公司之間的合作，這些公司正在開發伴隨診斷試劑盒以及新型療法。國家級基因組計劃正在擴展醫療保健基礎設施並促進定序的普及。各國政府已將基因組醫學視為一項策略性醫療保健能力，因為大規模人群定序有助於疾病預防、罕見疾病診斷、感染疾病監測和精準醫療規劃。因此，國家級定序舉措正在擴展檢查室基礎設施並促進標準化基因組數據的產生。

市場限制因素

高額的資本投入、持續的耗材支出以及專業的檢查室基礎設施推高了小規模醫療機構的實施成本。巨額資金需求對預算緊張的機構構成了障礙。解讀複雜的基因組數據需要經驗豐富的分子遺傳學家和生物資訊專家，這限制了其在資源匱乏的臨床環境中的應用。缺乏熟練人員降低了NGS服務的擴充性。監管合規、資料隱私要求和檢查室認證標準延長了臨床定序工作流程的檢驗週期。這些嚴格的要求延緩了實施過程，並增加了操作的複雜性。資料儲存和管理方面的挑戰進一步加重了處理大規模基因組資料集的檢查室的基礎設施負擔。

依產品類型
- 裝置
- 耗材和試劑
- 軟體和服務
按類型定序技術
- 合成定定序（SBS）
- 半導體定序
- 奈米孔定序
- 其他定序技術
基於工作流程
- 定序預處理
- 定序
- 數據分析
透過使用
- 臨床診斷
- 出於研究目的
- 藥物發現與開發
- 其他用途
最終用戶
- 醫院/診斷檢查室
- 學術研究機構
- 製藥和生物技術公司
- 其他最終用戶

第10章：全球次世代定序市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球次世代定序市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
中國
日本
印度
韓國
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Illumina, Inc.
Thermo Fisher Scientific Inc.

第13章：羅氏控股公司

安捷倫科技
BGI Genomics
KaiAjen NV
博雷德實驗室
Takara Bio Inc.
元素生物科學
Ultima Genomics
奇異基因組系統公司

第14章：全球次世代定序市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI061610956

The Next-Generation Sequencing Market is expected to grow at a CAGR of 14.5% from a market value of USD 24.9 billion in 2026 to USD 84.2 billion in 2035.

The next-generation sequencing market is undergoing fundamental transformation driven by the paradigm shift toward precision medicine and the integration of comprehensive genomic information into routine clinical practice. The market's evolution is characterized by the growing recognition that NGS enables simultaneous characterization of millions of nucleic acid fragments, providing comprehensive genomic, transcriptomic, epigenomic, and metagenomic insights essential for personalized healthcare. The convergence of advanced sequencing chemistries, automation, artificial intelligence, and cloud-based bioinformatics is enabling faster, more accurate, and increasingly accessible genomic analysis. Healthcare systems are incorporating NGS into routine diagnostic workflows because conventional diagnostic approaches evaluate limited biomarkers, whereas NGS identifies multiple clinically relevant variants within a single analytical workflow, reducing sequential testing and improving diagnostic confidence. Government agencies are supporting national genomic initiatives because population-scale sequencing contributes to disease surveillance, rare disease diagnosis, and healthcare planning. Pharmaceutical companies are expanding biomarker-driven clinical trials, creating sustained demand for sequencing technologies that support companion diagnostic development and translational research. The market is witnessing significant investment in integrated sequencing ecosystems, AI-enabled interpretation platforms, and long-read technologies, positioning NGS as a foundational technology supporting the continued evolution of precision healthcare across global healthcare systems.

Market Drivers

The expansion of precision oncology represents the primary driver for the next-generation sequencing market. Precision oncology represents the largest clinical application because modern cancer treatment increasingly depends on genomic characterization rather than tumor location alone. Hospitals are expanding comprehensive genomic profiling programs as oncologists require simultaneous identification of multiple actionable mutations that influence targeted therapy selection. Conventional molecular testing evaluates limited biomarkers, creating diagnostic delays when sequential testing becomes necessary. Diagnostic manufacturers are expanding NGS-based oncology portfolios through collaborations with pharmaceutical companies developing targeted therapies, resulting in sustained growth in sequencing utilization. Growing rare disease diagnosis is further accelerating market growth through expanded genomic testing adoption. Rare diseases frequently originate from inherited genetic abnormalities, making comprehensive sequencing a valuable diagnostic approach when conventional investigations remain inconclusive. Healthcare providers are increasingly incorporating exome and genome sequencing into diagnostic pathways because earlier molecular diagnosis shortens prolonged diagnostic journeys while supporting appropriate clinical management. Diagnostic laboratories continue investing in high-throughput sequencing infrastructure as demand for hereditary disease testing expands across pediatric and adult populations. Pharmaceutical biomarker development is strengthening sequencing utilization through expanded clinical trial integration. Drug development increasingly depends on molecular stratification because targeted therapies require identification of genetically defined patient populations during clinical development. Pharmaceutical sponsors are integrating sequencing throughout discovery, translational research, and clinical trials to improve biomarker identification and therapeutic response assessment. This requirement increases collaboration between sequencing platform providers and biopharmaceutical companies developing companion diagnostics alongside novel therapeutics. National genomic programs are expanding healthcare infrastructure and adoption. Governments recognize genomic medicine as a strategic healthcare capability because population-scale sequencing supports disease prevention, rare disease diagnosis, infectious disease surveillance, and precision healthcare planning. National sequencing initiatives are therefore expanding laboratory infrastructure while encouraging standardized genomic data generation.

Market Restraints

High capital investment, continuous consumable expenditure, and specialized laboratory infrastructure increase implementation costs for smaller healthcare institutions. The substantial financial requirements create barriers for facilities with constrained budgets. Complex genomic data interpretation requires experienced molecular geneticists and bioinformatics specialists, limiting adoption in resource-constrained clinical settings. The shortage of skilled personnel reduces the scalability of NGS services. Regulatory compliance, data privacy requirements, and laboratory accreditation standards increase validation timelines for clinical sequencing workflows. The rigorous requirements delay implementation and increase operational complexity. Data storage and management challenges create additional infrastructure burdens for laboratories handling large genomic datasets.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated sequencing ecosystems and workflow automation. Sequencing by synthesis remains the dominant technology with the largest installed instrument base, providing high accuracy and throughput for clinical and research applications. Semiconductor sequencing offers cost-effective solutions for targeted applications. Nanopore sequencing provides long-read capabilities for structural variant detection and complex genome analysis. Clinical laboratories are prioritizing complete sequencing solutions rather than standalone instruments because integrated automation, standardized bioinformatics, and recurring consumable supplies improve operational efficiency while supporting regulatory requirements. The segment analysis reveals that consumables and reagents represent the largest revenue-generating product category because every sequencing workflow depends on recurring purchases of library preparation kits, sequencing reagents, flow cells, quality control materials, and extraction products. Clinical laboratories are increasing testing volumes as oncology diagnostics, inherited disease testing, and infectious disease surveillance continue expanding across healthcare systems. Sequencing remains the core workflow stage because it directly determines analytical throughput, read quality, turnaround time, and overall laboratory productivity. Healthcare providers are adopting higher-capacity sequencing platforms as comprehensive genomic testing becomes routine across oncology, rare diseases, and translational research. Clinical diagnostics represents the fastest-growing application because genomic information increasingly influences diagnosis, prognosis, treatment selection, and disease monitoring across multiple therapeutic areas. Hospitals are integrating sequencing into routine diagnostic pathways as targeted therapies require comprehensive molecular characterization before treatment initiation. Academic and research institutes continue driving innovation and technology adoption. Pharmaceutical and biotechnology companies are expanding sequencing utilization for drug discovery and development. The integration of AI is becoming increasingly important because clinical sequencing generates complex datasets requiring efficient interpretation. AI-assisted variant interpretation reduces reporting time while improving analytical consistency across oncology and inherited disease testing.

Competitive and Strategic Outlook

The competitive landscape features established sequencing technology providers alongside specialized genomics and diagnostic companies. Illumina is a global market leader in short-read sequencing with one of the largest installed instrument bases worldwide, with a strategy focused on integrated sequencing ecosystems combining instruments, consumables, software, and clinical partnerships. Thermo Fisher Scientific provides comprehensive genomic workflow solutions spanning sample preparation, sequencing, bioinformatics, and clinical diagnostics, strengthening precision oncology through its Oncomine portfolio and companion diagnostic collaborations. Roche leverages its global diagnostics leadership to integrate NGS with molecular diagnostics and personalized medicine, with strategic investments continuing to expand companion diagnostics and oncology-focused genomic testing capabilities. Agilent Technologies focuses on target enrichment, sample preparation, quality control, and automated genomics workflows, enhancing laboratory productivity through integrated solutions supporting clinical and translational research. QIAGEN specializes in sample technologies, bioinformatics, and clinical interpretation solutions that complement sequencing platforms, with a strategy emphasizing companion diagnostics, molecular testing, and precision medicine partnerships. BGI Genomics operates one of the world's largest genomic sequencing service networks with strengths in population genomics, reproductive health, and infectious disease surveillance. Companies are pursuing product portfolio expansion through innovation in sequencing chemistry, automation, AI-enabled bioinformatics, and long-read technologies. Strategic collaborations between sequencing providers, pharmaceutical companies, and healthcare systems are increasing, driven by the need for companion diagnostic development and clinical validation. Recent key developments include Meridian Bioscience and 4bases announcing a collaboration to enable rapid, globally scalable NGS workflows. Hartwig Medical Foundation and Ultima Genomics expanded their strategic collaboration by adopting Ultima's UG200 system to advance WGS in oncology care. Ultima Genomics launched the UG200 Series sequencing instruments with higher output and faster runtime. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

The next-generation sequencing market is positioned for sustained growth driven by the convergence of precision oncology, rare disease diagnosis, pharmaceutical biomarker development, and national genomic programs. The transition from a research-driven industry toward a clinically integrated diagnostics ecosystem represents a fundamental shift in genomic medicine. While challenges related to high costs, interpretation complexity, and regulatory requirements persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with NGS evolving into a foundational technology supporting precision healthcare, pharmaceutical innovation, and public health surveillance across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Next-Generation Sequencing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Sequencing Workflow Overview
3.8 Technology Evolution and Adoption Trends
3.9 Installed Base Analysis
3.10 Sequencing Throughput Analysis
3.11 Sample Volume Analysis
3.12 End-user Adoption Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Sequencing Technologies
6.2 Product Innovation
6.3 Sequencing Chemistry and Platform Advancements
6.4 Clinical Trial Analysis
6.5 Pipeline Analysis
6.6 AI Integration in NGS Data Analysis
6.7 Bioinformatics and Cloud-based Data Management
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Next-Generation Sequencing Market Landscape Analysis

8.1 Analysis by Product Type
8.2 Analysis by Sequencing Technology
8.3 Analysis by Workflow
8.4 Analysis by Sequencing Type
8.5 Analysis by Application
8.6 Analysis by End User

9. Global Next-Generation Sequencing Market Segment Analysis (2021-2035)

9.1 By Product Type
- 9.1.1 Instruments
- 9.1.2 Consumables & Reagent
- 9.1.3 Software & Services
9.2 By Sequencing Technology
- 9.2.1 Sequencing by Synthesis (SBS)
- 9.2.2 Semiconductor Sequencing
- 9.2.3 Nanopore Sequencing
- 9.2.4 Other Sequencing Technologies
9.3 By Workflow
- 9.3.1 Pre-Sequencing
- 9.3.2 Sequencing
- 9.3.3 Data Analysis
9.4 By Application
- 9.4.1 Clinical Diagnostics
- 9.4.2 Research Applications
- 9.4.3 Drug Discovery & Development
- 9.4.5 Other Applications
9.5 By End User
- 9.5.1 Hospitals & Diagnostic Laboratories
- 9.5.2 Academic & Research Institutes
- 9.5.3 Pharmaceutical & Biotechnology Companies
- 9.5.4 Other End Users

10. Global Next-Generation Sequencing Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Next-Generation Sequencing Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 China
11.10 Japan
11.11 India
11.12 South Korea
11.13 Australia
11.14 Brazil
11.15 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Illumina, Inc.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Thermo Fisher Scientific Inc.